Drug Resistance in Cancer Cells

1. Front Matter

   Pages i-xvii

   PDF

2. Multidrug Resistance Mediated by MDR-ABC Transporters

   • Gergely Szakács, Kenneth Kin Wah, Orsolya Polgár, Robert W. Robey, Susan E. Bates

   Pages 1-20

3. Metastasis and Drug Resistance

   • Dominic Fan, Sun-Jin Kim, Robert L. Langley, Isaiah J. Fidler

   Pages 21-52

4. The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer

   • Tomohisa Yokoyama, Yasuko Kondo, Oliver Bögler, Seiji Kondo

   Pages 53-71

5. Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors

   • Stacey J. Baker, E. Premkumar Reddy

   Pages 73-93

6. Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells

   • Kapil Mehta, Jansina Y. Fok

   Pages 95-114

7. Extracellular Matrix-Mediated Drug Resistance

   • P.S. Hodkinson, Tariq Sethi

   Pages 115-135

8. Oxidative Stress and Drug Resistance in Cancer

   • Dunyaporn Trachootham, Wan Zhang, Peng Huang

   Pages 137-175

9. Nuclear Factor-κB and Chemoresistance: How Intertwined Are They?

   • Ajaikumar B. Kunnumakkara, Preetha Anand, Bharat B. Aggarwal

   Pages 177-208

10. Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers

    • Zahid H. Siddik

    Pages 209-231

11. Resistance to Differentiation Therapy

    • Bulent Ozpolat

    Pages 233-255

12. MicroRNAs and Drug Resistance

    • Elisa Barbarotto, George A. Calin

    Pages 257-270

13. Molecular Signatures of Drug Resistance

    • Melissa A. Troester, Jason I. Herschkowitz, Katherine A. Hoadley

    Pages 271-294

14. Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging

    • Natalie Charnley, Catharine West, Pat Price

    Pages 295-313

15. Overcoming Drug Resistance by Phytochemicals

    • Marion M. Chan, Dunne Fong

    Pages 315-342

16. Back Matter

    Pages 343-363

    PDF

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

• apoptosis
• cancer
• cancer therapy
• cell
• chemoresistance
• cytokine
• cytokines
• drug
• drug design
• drug resistance
• imaging
• metastasis
• resistance
• tissue
• tumor

Policies and ethics